Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab

Trastuzumab plus chemotherapy is the standard of care for the first-line treatment of patients with HER2+ advanced esophagogastric (EG) cancer. Nevertheless, patients frequently develop resistance. In preclinical models, we identified the overexpression of Fibroblast Growth Factor Receptor (FGFR) 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecchetto, Camilla, Quinzii, Alberto, Casalino, Simona, Gaule, Marina, Pesoni, Camilla, Merz, Valeria, Pietrobono, Silvia, Mangiameli, Domenico, Pasquato, Martina, Milleri, Stefano, Giacopuzzi, Simone, Bencivenga, Maria, Tomezzoli, Anna, de Manzoni, Giovanni, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051335/
https://www.ncbi.nlm.nih.gov/pubmed/36983691
http://dx.doi.org/10.3390/jpm13030508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051335/
https://www.ncbi.nlm.nih.gov/pubmed/36983691
http://dx.doi.org/10.3390/jpm13030508

Ejemplares similares